Clinical Trials Logo

Clinical Trial Summary

The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02725476
Study type Interventional
Source Xencor, Inc.
Contact
Status Completed
Phase Phase 2
Start date March 2016
Completion date December 2017

See also
  Status Clinical Trial Phase
Terminated NCT04918147 - Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) Phase 2